Andreasen, Camilla http://orcid.org/0000-0002-8005-6869
Dahl, Cecilie http://orcid.org/0000-0001-8143-0907
Solberg, Lene B. http://orcid.org/0000-0002-8705-5033
Borgen, Tove T. http://orcid.org/0000-0002-5012-0903
Wisløff, Torbjørn http://orcid.org/0000-0002-7539-082X
Gjertsen, Jan-Erik http://orcid.org/0000-0002-8490-268X
Figved, Wender http://orcid.org/0000-0002-8201-9818
Stutzer, Jens M. http://orcid.org/0000-0003-3512-2414
Nissen, Frida I. http://orcid.org/0000-0002-1325-2608
Nordsletten, Lars http://orcid.org/0000-0003-4642-5787
Frihagen, Frede http://orcid.org/0000-0002-4811-669X
Bjørnerem, Åshild http://orcid.org/0000-0002-3123-2950
Omsland, Tone K. http://orcid.org/0000-0002-0808-3133
Funding for this research was provided by:
The Regional Health Authorities (243852)
The North Norwegian Health Authorities (14083)
Vestre Viken Hospital Trust (1903007)
UiT The Arctic University of Norway
Article History
Received: 27 March 2023
Accepted: 24 November 2023
First Online: 12 December 2023
Declarations
:
: The study was approved by the Regional Committee for Medical and Health Research Ethics. The University of Oslo performed a Data Protection Impact Assessment (DPIA) in agreement with the General Data Protection Regulation. The study on validation of the S52 diagnosis was approved by the Norwegian Directorate of Health and Norwegian Agency for Shared Services in Education and Research. In addition, the University of Oslo performed a separate DPIA.
: The funders had no role in the design or conduction of the study, as well as collection, analyses, or data interpretation.
: CA, CD, LBS, TW, JMS, FIN, LN, ÅB, and TKO report no support from any organization for the submitted work; TTB reports speaker fees from UCB, Amgen, Roche, and Pharma Prim. Advisory board for UCB; JEG reports speaker fees from Ortomedic Norway and LINK Norway; WF reports speaker fees from Ortomedic and Zimmer Biomet; FF reports speaking fees from UCB and Amgen.